XenoPort to Release Fourth Quarter and Year-End Financial Results on February 19, 2015
February 05 2015 - 10:00AM
Business Wire
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will
release its fourth quarter and year-end financial results on
February 19, 2015 at approximately 4:30 p.m. Eastern Time. The
company will host a conference call at 5:00 p.m. Eastern Time that
same day to provide a summary of its financial results and general
business updates. A replay of the call will be available for one
week following the event.
To access the conference call via the Internet, go to
www.XenoPort.com. Please join the call at least 15 minutes prior to
the start to ensure time for any software downloads that may be
required.
To access the live conference call via phone, dial
1-888-275-3514. International callers may access the live call by
dialing 706-679-1417. The reference number to enter the call is
77034895.
The replay of the conference call may be accessed that same day
after 8:00 p.m. Eastern Time, via the Internet, at
www.XenoPort.com, or via phone at 1-855-859-2056 for domestic
callers, or 404-537-3406 for international callers. The reference
number to enter the replay of the call is 77034895.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
developing and commercializing a portfolio of internally discovered
product candidates for the potential treatment of neurological
disorders. XenoPort is currently commercializing HORIZANT®
(gabapentin enacarbil) Extended-Release Tablets in the United
States and developing its novel fumaric acid ester product
candidate, XP23829, as a potential treatment for patients with
moderate-to-severe chronic plaque-type psoriasis and/or relapsing
forms of multiple sclerosis. REGNITE® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort granted exclusive world-wide rights for the
development and commercialization of its clinical-stage oral
product candidate, arbaclofen placarbil, to Indivior PLC for all
indications. XenoPort's pipeline of product candidates also
includes a potential treatment for patients with idiopathic
Parkinson's disease.
To learn more about XenoPort, please visit the Website at
www.XenoPort.com.
XENOPORT, HORIZANT and REGNITE are registered trademarks of
XenoPort, Inc.
XNPT2F
XenoPort, Inc.Jackie Cossmon, 408-616-7295ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024